New hope for rare blood cancers: targeted drug trial opens

NCT ID NCT06716658

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers will track how many respond and what side effects occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic lymphoproliferative disorder of NK-cells Leukemia, Large Granular Lymphocytic mycosis fungoides primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma T-cell large granular lymphocyte leukemia T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T CELL LYMPHOMA CUTANEOUS T CELL LYMPHOMA (CTCL) INDOLENT T-CELL LYMPHOPROLIFERATIVE DISORDER OF THE GASTROINTESTINAL TRACT LARGE GRANULAR LYMPHOCYTE LEUKEMIA LARGE GRANULAR LYMPHOCYTIC LEUKEMIA LYMPHOMA, T-CELL MYCOSIS FUNGOIDES NK-LGL LEUKEMIA PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA T-LGL LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital
NOT_YET_RECRUITING

Tianjin, 300020, China
Institute of Hematology & Blood Diseases Hospital, China
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact